Melanotan II and Sleep

Among users of Melanotan II you can find complaints of worsened sleep - restless nights, waking from nausea or erections, a feeling of heat. Others, on the contrary, confuse it with melatonin and consider it a "sleep peptide." The editorial team examined which mechanisms might link MT-II to sleep and how well these links are supported by research.

Melanotan, melanin, and melatonin: not to be confused

The names "melanotan," "melanin," and "melatonin" sound similar but denote entirely different substances. Melanin is the pigment of the skin, hair, and eyes. Melatonin is a hormone of the pineal gland, synthesized from tryptophan via serotonin, that signals to the body the onset of the dark part of the day. Melanotan II is a synthetic peptide, an analog of alpha-melanocyte-stimulating hormone.

The common root "melan-" (from the Greek for "black") is connected to the history of their discoveries: both melatonin and α-MSH were initially studied for their effect on the pigmentation of amphibian skin. But biochemically these are unrelated molecules with different receptors and different functions.

Therefore the claim that Melanotan II "improves sleep like melatonin" has no basis. MT-II does not act on the melatonin receptors MT1 and MT2 and is not a means of regulating circadian rhythms. Any comparison of these substances by their effect on sleep is incorrect.

Melanocortins and the regulation of arousal

The brain's melanocortin system is located in the hypothalamus - the very region that houses the centers regulating sleep and wakefulness, body temperature, and eating behavior. Neurons that produce proopiomelanocortin (POMC) interact closely with other neural networks of the hypothalamus, in particular those controlling energy balance and the autonomic nervous system (Cone, 2006).

Activation of the MC4R receptor increases the activity of the sympathetic nervous system. For the related peptide bremelanotide this manifests as a moderate transient rise in blood pressure, documented in the official prescribing information. Sympathetic activation generally does not promote falling asleep: it is associated with a state of readiness, not rest.

In classic animal experiments, central administration of α-MSH and its analogs produced characteristic behavior with yawning and stretching, as well as increased grooming. Interestingly, yawning was also described in humans in early studies of MT-II (Dorr et al., 1996). Yawning does not mean sleepiness - in physiology it is viewed rather as a sign of a change in the level of arousal.

So from the standpoint of mechanism, one can expect that melanocortin stimulation raises arousal rather than promotes sleep. However, this is a theoretical conclusion: there are no targeted studies of sleep architecture during MT-II use.

Side effects that can disrupt sleep

The most likely connection of MT-II to sleep is mediated by side effects. In pilot studies the most frequent reactions were nausea, facial flushing, yawning, decreased appetite, and spontaneous erections in men (Dorr et al., 1996; Wessells et al., 1998). Each of these effects, occurring in the evening, is capable of complicating falling asleep.

Nausea is a centrally mediated effect of melanocortin agonists. For bremelanotide it is the most frequent adverse reaction in the official data. Nausea in bed, especially in a horizontal position, is a common cause of restless sleep and nighttime awakenings.

Spontaneous erections are described in studies of MT-II as one of the expected effects. If they occur at night and last a long time, this not only interferes with sleep but can also be a sign of a dangerous condition. An erection lasting more than four hours is priapism, which requires urgent medical care.

• Nausea and stomach discomfort- difficulty falling asleep.
• Flushing and a feeling of heat- discomfort, sweating at night.
• Spontaneous erections- awakening; a prolonged erection requires a doctor's help.
• Increased blood pressure and pulse- palpitations, restlessness.

The psychological factor deserves a separate mention. Anxiety over the appearance of new moles, unexpected pigmentation, or unclear symptoms can also worsen sleep, especially if a person is using an unregistered drug without medical supervision.

What the clinical data say

Clinical studies of Melanotan II are limited to a few small papers from the 1990s. They studied pigmentation and erectile function, and safety was assessed by a general list of side effects. Polysomnography, sleep quality scales, and sleep duration were not measured.

For bremelanotide, a close relative of MT-II, the phase 3 study (Kingsberg et al., 2019) also focused mainly on nausea, flushing, headache, and blood pressure changes. Insomnia was not singled out as a characteristic effect, but it was not specifically studied either. Moreover, bremelanotide is used episodically rather than regularly, which may reduce its impact on nighttime rest.

Reviews of the illicit use of melanotans (Evans-Brown et al., 2009; Habbema et al., 2017) focus on dermatological and cardiovascular risks. User reports of sleep disturbances exist, but they are not systematized and do not allow distinguishing the effect of the peptide itself, impurities, accompanying substances, and expectations.

So the honest answer to the question "does MT-II affect sleep" is "there is not enough data." The mechanisms through which such an effect is possible exist, but their clinical significance has not been established.

Sleep hygiene and when to see a doctor

Regardless of the cause, sleep disturbances should be approached comprehensively. A regular schedule, a dark cool bedroom, limiting caffeine in the second half of the day, and avoiding gadgets before bed are basic recommendations whose effectiveness is confirmed for the general population.

People who combine melanotans with other substances - stimulants, fat burners, erectile-function drugs - should remember that poor sleep may be a cumulative effect. It is difficult to identify the culprit on your own in such a situation.

You must see a doctor urgently in the case of an erection lasting more than four hours, a severe headache, chest pain, pronounced palpitations, or a sharp rise in blood pressure. A scheduled consultation is needed for persistent insomnia, the appearance of new or changed moles, and any unclear symptoms.

For athletes, quality sleep is one of the key factors of recovery. Lost sleep worsens strength performance, cognitive function, and hormonal balance, so the risk of disrupting it must be taken into account when evaluating any substance.

Editorial conclusions

Melanotan II has nothing in common with melatonin and is not a means of improving sleep. The similarity of the names is merely a historical coincidence.

There are no direct studies of MT-II's effect on sleep. However, its known side effects - nausea, flushing, spontaneous erections, and sympathetic activation - are theoretically capable of disrupting nighttime rest.

Any alarming symptoms, especially a prolonged erection or blood pressure spikes, require medical help rather than "waiting it out" on your own.

We also recommend our materials "PT-141 (Bremelanotide) and Sleep," "Myths About Melanotan II," and "Melanotan II and Carbohydrate Metabolism."

References

1. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784.
2. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393.
3. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–749.
4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908.
5. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009;338:b566.
6. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975–980.
7. Vyleesi (bremelanotide injection), for subcutaneous use. Prescribing information. U.S. Food and Drug Administration; 2019.